Prediction of bladder tumor relapse based on the risk factors and characteristics of the treatment.
DOI:
https://doi.org/10.26641/2307-0404.2015.1.40240Keywords:
tumors, urinary bladder, prognosis, recurrence, infection, probioticsAbstract
Objectives. To investigate the possibility of predicting recurrence of bladder tumors based on the clinical and morphological features of the disease and preoperative intravesical instillation of probiotic Aerococcus viridans 167. 190 patients operated for bladder tumors have been observed for a period from 1 to 73 months (mean 35.2 months). In 51 patients one single preoperative intravesical instillation of probiotic Aerococcus viridans 167 was added to a standard treatment. Reported cases of recurrence of tumors were used as a basis for the development of mathematical rules for predicting recurrences. These rules have been used to create a logistic regression and support vector machines. Of 190 patients, in 132 (69,5%) transitional cell carcinoma (TCC) in the stage Ta-T1, in 58 (30,5%) - transitional cell papilloma of the bladder (TCP) was identified. Recurrences were detected in 52 (27.4%) patients, mean time of observation was 14.7 (1-50 months). In patients with TCC recurrence was observed in 36 (37%) of 96 patients not treated with probiotic instillation vs 7 (19%) of 36 after probiotic use (p> 0,05). In TCP group no significant signs of the instillation influence of probiotics on the number of relapses were revealed. Classification rules that can predict the risk of recurrence of bladder tumors based on histological characteristics and application of probiotic were obtained. Preoperative instillation of probiotic Aerococcus viridans 167 in TCC TaT1 patients reduces the recurrence rate from 37% to 19% (p <0,05). Variables "Number of tumors" and "Maximum tumor size," and their relationship are informative prognostic parameters. The rules obtained may be recommended to follow up patients after surgery for timely distinguishing group of patients with increased risk of bladder tumor recurrence.
References
Ryzhenko SA, Kremenchutsky GN, Bredykhyna MO, Kovalenko SM. [Investigation of probitic strain A. viridans 167 on inoculation on cell culture]. Annals of Mechnicov Institute.2007;1:19-22. Ukrainian. 2. Molchanov RM, Shpon’ka IS, Slyusarev VM. [Impact of A-bacterinum on indices of local immunity in patients with superficial cystic cancer]. Urologija. 2012;16(3):31-37. Russian. 3. Molchanov RM, Korolenko AS. [Impact of bacte¬rial factor on development of cystic cancer in expe¬riment]. Urologija. 2006;10(3):23-26. Ukrainian. 4. Kawai K, Miyazaki J, Joraku A, Nishiyama H, Akaza H. Bacillus Calmette-Guerin (BCG) immuno¬therapy for bladder cancer: current understanding and per¬spectives on engineered BCG vaccine. Cancer science. 2013;104(1):22-7. Epub 2012/11/28. doi: 10.1111/ cas.12075. PubMed PMID: 23181987. 5. Cristianini N, Shawe-Taylor J. An introduction to support vector machines : and other kernel-based learning methods. Cambridge, New York: Cambridge University Press, 2000;xiii:189. 6. Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Comperat E, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. European urology. 2013;64(4):639-53. Epub 2013/07/06. doi: 10.1016/j.eururo.2013.06.003. PubMed PMID: 23827737. 7. Ikeda M, Motoshima T, Kurosawa K, Fujii Y, Miyakawa J, Kamigaito T, et al. [Efficacy and safety of maintenance intravesical instillation therapy with bacillus Calmette-Guerin and epirubicin for non-muscle invasive bladder cancer]. Hinyokika Kiyo. 2013;59(3):153-7. Epub 2013/05/02. PubMed PMID: 23633629. 8. Gray R, Begg CB, Greenes RA. Construction of receiver operating characteristic curves when disease verification is subject to selection bias. Medical decision making: an international journal of the Society for Me¬dical Decision Making. 1984;4(2):151-64. Epub 1984/01/01. PubMed PMID: 6472063. 9. Hosmer DW, Lemeshow S. Applied logistic regression. 2nd ed. New York: Wiley, 2000;xii:373. 10. Seow SW, Cai S, Rahmat JN, Bay BH, Lee YK, Chan YH, et al. Lactobacillus rhamnosus GG induces tumor regression in mice bearing orthotopic bladder tumors. Cancer science. 2010;101(3):751-8. Epub 2009/12/18. doi:10.1111/j.1349-7006.2009.01426.x. PubMed PMID: 20015287. 11. Kanmani P, Satish Kumar R, Yuvaraj N, Paari KA, Pattukumar V, Arul V. Probiotics and its functionally valuable products-a review. Critical reviews in food science and nutrition. 2013;53(6):641-58. Epub 2013/05/01. doi: 10.1080/10408398.2011.553752. PubMed PMID: 23627505. 12. van Rhijn BW, Burger M, Lotan Y, Solsona E, Stief CG, Sylvester RJ, et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. European urology. 2009;56(3):430-42. Epub 2009/07/07. doi: 10.1016/ j.eururo.2009.06.028. PubMed PMID: 19576682.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2017 Medical Perspectives
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Submitting manuscript to the journal "Medicni perspektivi" the author(s) agree with transferring copyright from the author(s) to publisher (including photos, figures, tables, etc.) editor, reproducing materials of the manuscript in the journal, Internet, translation into other languages, export and import of the issue with the author’s article, spreading without limitation of their period of validity both on the territory of Ukraine and other countries. This and other mutual duties of the author and all co-authors separately and editorial board are secured by written agreement by special form to use the article, the sample of which is presented on the site.
Author signs a written agreement and sends it to Editorial Board simultaneously with submission of the manuscript.
